The new 20nm process produces an 8-gigabyte (GB) multi-level cell (MLC) NAND flash device, providing a high-capacity, small form factor storage option for saving music, video, books and other data on smartphones, tablets and computing solutions such as solid-state drives (SSDs).
British-based AECOM, Inc. and the University of Wisconsin-Milwaukee (UWM) have signed a Memorandum of Agreement to explore potential areas of research collaboration in the rapidly growing area of nanotechnology in building materials.
GMZ Energy Inc., a maker of thermoelectric materials based on nanotechnology developed at MIT, has raised $7 million from a planned $13 million investment round, the first institutional round for the company.
Shrink Nanotechnologies, Inc., an innovative high technology company announced that critical intellectual property for Shrink's Cell Align cell culturing and tissue engineering material, along with a novel higher performing immunoassay substrate has been filed with the US Patent and Trademark Office.
By working together to further co-develop Addressable Memory technology, PARC and Thinfilm are complementing each other's strengths to move the industry beyond components and devices towards consumer-facing applications.
The new 20nm process produces an 8-gigabyte multi-level cell NAND flash device, providing a high-capacity, small form factor storage option for saving music, video, books and other data on smartphones, tablets and computing solutions such as solid-state drives.
Under the terms of the agreement, Definiens and Leica will cooperatively market their complementary products and host joint workshops and educational events. Customers will benefit from streamlined high-content image analysis, allowing them to better identify and understand pathways and mechanisms.
During a recent visit to Finland, Indian Minister for New and Renewable Energy, Mr Farooq Abdullah, met Finnish Minister of the Environment, Mrs Paula Lehtomaki, together with Cleantech Finland officials and member companies, including Beneq.
Access Pharmaceuticals, Inc., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.